MedTrace Logo

Irinotecan in Treating Patients With Colorectal Cancer

NCT00003843 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2015-02-16

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have colorectal cancer.

Conditions

Interventions

DRUG

irinotecan hydrochloride

GENETIC

mutation analysis

GENETIC

polymorphism analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • California Cancer Consortium

    lead NETWORK

Principal Investigators

  • Heinz-Josef Lenz, MD · University of Southern California

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31
Primary Completion
2001-02-28
Completion
2001-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003843 on ClinicalTrials.gov